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 2 
Abstract 30 
Whether there is any association between urinary incontinence and menopause is the subject 31 
of debate, partly due to the fact it is difficult to tell the difference between the effects of 32 
menopause and those of ageing. For some time it was hoped that hormonal treatment for 33 
menopause would be beneficial for urinary incontinence because there are hormonal receptors 34 
in the urinary tract. The goal of this survey of current knowledge on the subject is to explore 35 
thoroughly the relationship between menopause and urinary incontinence . 36 
Our study is based on a review of the literature dealing with the epidemiology of urinary 37 
incontinence in women aged between 45 and 60, and the effects of hormonal treatment with 38 
respect to the symptoms of involuntary loss of urine.  39 
Analysis of the epidemiological data drawn from large cohorts shows that on the one hand, 40 
the menopause has little if any impact on the risk of urinary incontinence, and on the other 41 
hand that the effects of œstrogen medication on urinary incontinence vary according to how it 42 
is administered and the type of incontinence. The effect of oral hormone treatments for 43 
menopause is rather negative with respect to stress incontinence. Vaginal treatment appears to 44 
be beneficial for overactive bladder symptoms. 45 
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1. Introduction 52 
The menopause is a universal physiological event related with the drop in ovarian hormone 53 
secretions (œstrogens and progestin) that occurs as the stock of ovarian follicules is depleted. 54 
Menopause is diagnosed when menstruation has stopped for 12 successive months, and the 55 
average age at which it occurs is between 47 and 51 [1,2]. Its clinical expression varies very 56 
considerably between socio-cultural groups and individuals [3]. These variations depend on 57 
many factors, such as women's social status, their nutrition, life style (smoking) and weight, 58 
not forgetting genetic factors [3]. It is difficult to draw the distinction between the effects of 59 
menopause and those of ageing. In addition to the menopausal "syndrome" itself, which 60 
mainly comprises vasomotor symptoms and vaginal dryness, urinary symptoms including 61 
incontinence (UI) have been attributed to menopause. The hormonal dependence of the 62 
genital tract tissues has been evoked in order to explain the appearance of these female low 63 
urinary tract symptoms (FLUTS) at the menopause. Œstrogen receptors have been found not 64 
only in the pelvic floor muscles but also in the uro-genital ligaments and detrusor muscle cells 65 
along with the connective tissues and all the fascias that maintain a stable relationship 66 
between the various organs [2].  67 
Urinary incontinence can be defined as "the complaint of any involuntary leakage of urine" 68 
[4]. The standard classification gives three main types of UI: Stress Urinary Incontinence 69 
(SUI), Urge Urinary Incontinence (UUI) and Mixed Urinary Incontinence (MUI). Stress 70 
urinary incontinence is characterised by involuntary loss of urine without any previous feeling 71 
of a need to void, which takes place on the occasion of a physical stress (cough, lifting 72 
something heavy, or any other physical activity). Urge urinary incontinence (or urgent need to 73 
void) is characterised by involuntary loss of urine preceded by an urgent and irresistible need 74 
to void resulting in uncontrollable leakage of urine. Mixed urinary incontinence is the 75 
association in variable proportions of SUI and UUI.  76 
UI may be experienced simply as a nuisance or as a real handicap [5,6]. Women frequently 77 
present the symptoms of UI, but the estimates for its prevalence in the general population vary 78 
widely, from 8 to 30 %. This variability is due not only to the very heterogeneous nature of 79 
the populations studied but also to the varying definitions of UI used in the studies.  80 
Many different factors are associated with an increased risk of UI [7]. The main of these are 81 
ageing, pregnancy, childbirth, past history of pelvic and perineal surgery, obesity, and chronic 82 
pathologies (diabetes, cognitive problems, etc.). There is more debate about the roles of 83 
menopause and hormone replacement therapy (HRT) [8,9]. As mentioned above, it is difficult 84 
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to differentiate between the role of ageing and that of the menopause, and equally to 85 
differentiate the true role of menopause from that of treatments instigated at the time of 86 
menopause, such as HRT.  87 
The relationship postulated between UI and hormone deficiencies induced by menopause is 88 
based mainly on "physiological" data, i.e. the existence of (œstrogen and progestin) hormonal 89 
receptors in the epithelial tissues of bladder, urethra and trigone and also in the vagina, 90 
uterosacral ligaments, levator ani and puborectal muscles [10]. The other argument supporting 91 
this relation is clinical observation of an increase in the prevalence of overactive bladder 92 
(OAB) syndrome after the menopause. The lack of œstrogens could contribute in various 93 
ways to other urinary symptoms that arise: œstrogens play a role in (i) the increase in 94 
epithelial cellular trophicity in the vagina, urethra and bladder (ii) the increase in peri-urethral 95 
vascularisation (an important factor for regulation of closing pressure), (iii) the increase in 96 
maximum closing pressure and (iv) the increase in concentration and sensitivity of -97 
adrenergic receptors with modification of the -adrenergic receptors/-adrenergic receptor 98 
ratio in favour of the -adrenergic receptors [11-13]. Progestin receptors are also to be found 99 
in the entire female genital tract, although in less constant fashion than œstrogen receptors. 100 
Progestin appears to have a detrimental effect on continence, by reducing muscle tone of 101 
bladder and urethra [10].  102 
The aim of our review is to analyse the data in the literature with respect to the relationship 103 
between menopause and UI. We present the main epidemiological data dealing with the 104 
relationship between prevalence, incidence and remission of UI, and the menopause. We then 105 
try to supply answers to the two main questions raised by this relationship: What 106 
consequences do hormonal changes at the menopause have on UI symptoms? What 107 
consequences do hormonal treatments have on continence?  108 
 109 
2. Methods: 110 
A review of the literature was carried out by consulting the Medline database entries between 111 
January 2000 and June 2012. Articles were selected by cross-referencing the following 112 
keywords: "urinary incontinence, stress urinary incontinence, urge incontinence, overactive 113 
bladder, menopause, œstrogen therapy". In this selection priority was given to meta-analyses, 114 
literature reviews, randomised controlled trials and cohort studies. The level of evidence (LE) 115 
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scale proposed by the Oxford Centre for Evidence-Based Medicine (www.cebm.net) was used 116 
to class the articles selected.  117 
The terminology used complies with International Continence Society (ICS) and 118 
International UroGynecological Association (IUGA) recommendations. 119 
 120 
3. Results 121 
3.1. Study selection 122 
Among the 488 articles initially selected during the Medline search, 29 articles were finally 123 
retained, including 3 meta-analyses, 4 literature reviews, 5 randomised controlled trials and 12 124 
cohort studies. Figure 1 gives details on this selection of articles. 125 
 126 
3.2. Prevalence or incidence of UI according to age 127 
The prevalence of urinary incontinence is proportional to age. The distribution of the various 128 
types of UI changes with age.Several articles report a peak in the prevalence of SUI at midlife 129 
(LE3). The majority of cases before the age of 50 are SUI, but after that age it represents a 130 
minority [14]. After 60 it is mixed UI that predominates. The prevalence of UI at the time of 131 
menopause varies from 8 to 27 % depending on the population studied and the definition used 132 
for UI [14-17] (LE2). 133 
Only a few cohort studies specifically address the menopause period (45-60 years). Mac 134 
Grother et al. report an annual incidence of UI of 8% in a population of 108 women aged 135 
between 40 and 59 in the general population [16] (LE3). Two other cohorts of women under 136 
the age of 60 found annual incidence rates at 4 and 5 % [15, 17] (LE3). In another cohort of 137 
2860 femmes between 40 and 60, the authors report an annual incidence rate of 6% [18] 138 
(LE3). A longitudinal study of a cohort of nurses aged 36 to 55 by Townsend et al. found an 139 
annual incidence of 7% [19] (LE3).  140 
There is considerable disparity between the cohort studies concerning the annual rate of 141 
remission. On the one hand Hagglund [17], Samuelsson [20], and Townsend [19] report 142 
annual remission rates for UI of 4, 6, and 7% respectively (LE3). On another hand other 143 
authors report higher annual remission rates, at 25 to 29% [16, 18] (LE3). These results can be 144 
explained in part by the definition of remission of UI depending on the studies: complete 145 
disappearance or lessening of the severity of UI symptoms. 146 
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 147 
3.3. Prevalence or incidence of UI according to menopausal status 148 
The American prospective cohort Study of Women’s Health Across the Nation (SWAN) 149 
followed 1529 women, without any UI symptoms at inclusion, annually for 6 years. The 150 
women were classed according to their hormonal status at the end of the study as follows: pre-151 
menopause, early peri-menopause (irregular menses), late peri-menopause (3 to 11 months 152 
amenorrhoea), and post-menopause (over 12 months amenorrhoea). The peri-menopause 153 
period is associated with an increased risk of UI for all types of UI together (OR= 1.52 [95% 154 
CI: 1.12Ŕ2.05] in late peri-menopause) but this association disappears post-menopause (0.88 155 
[0.63-1.23]). Analysis by the type of UI shows that this association with the peri-menopause 156 
above all concerns UUI (2.12 [1.26-3.56] in late peri-menopause) while the association is non 157 
significant for SUI (1.24 [0.75-2.05] in late peri-menopause). Analysis of frequent UI alone 158 
(at least one episode of UI a week) does not show any association with early peri-menopause 159 
(0.99 [0.60-1.63]), late peri-menopause (1.14 [0.51-2.54]), or post-menopause (1.10 [0.46-160 
2.64]) (LE2) [21]. In another study covering 2415 women from the SWAN cohort who were 161 
incontinent (at least one episode of UI per month) at inclusion, Waetjen reports that the 162 
worsening of UI symptoms observed after the menopause is not attributable to the menopause 163 
itself [22] but to an increase in weight. The menopause appears to be associated with an 164 
increase in weight and this would explain the increase in the prevalence of UI (LE2). 165 
The study by Sherburn et al. of the Australian cohort of 1897 femmes, The Melbourne 166 
Women’s Midlife Health Project, addressed the impact of the menopause on UI symptoms. 167 
Simultaneous cross-sectional and longitudinal analysis of the data did not reveal any 168 
statistical relationship between UI and menopause (LE3). In the longitudinal analysis of 438 169 
women from the same cohort who were followed for 7 years the menopause was not 170 
associated with any increase in the incidence of UI as a whole (LE3) [15].  171 
The results obtained by another longitudianl study, the National Survey of Health and 172 
Development (NSHD) concerning 1211 women between 48 and 54 years of age did not find 173 
any association between menopause and UUI (LE3). SUI alone was associated with the 174 
hormonal status, since in this study the peri-menopause was associated with an increased 175 
prevalence of urine leakage symptoms due to stress, as compared with the group of post-176 
menopausal women (OR= 1, 39 [1, 4-1, 7]) (LE3). This study, in which it is not possible to 177 
distinguish clearly between the effects of age and those of menopause because there is no 178 
comparison of the incidence rates between the different groups, nevertheless appears to reveal 179 
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an effect of ageing independent of that of the menopause with respect to the occurrence of 180 
UUI or SUI (LE3) [23].  181 
A large Chinese cross-sectional study of nearly 20 000 women aged 20 to 99 shows an 182 
association between SUI and menopause (OR= 1, 26 [1, 04-1, 52]), even when age is taken 183 
into account as a risk factor (LE4) [24]. 184 
 185 
3.4. Prevalence or incidence of UI according to hormone levels 186 
A recent cohort study looked at the effect of changes in œstrogen concentrations on urinary 187 
symptoms during the transition to menopause. A big drop in œstrogen levels is associated in 188 
significant fashion with an improvement in UI symptoms (LE2) [25]. Moreover, analysis of 189 
the annual fluctuation in endogenous œstrogen levels during the menopausal period using the 190 
data from SWAN did not find any association with the onset of UI or worsening of UI 191 
symptoms (LE2) [26]. A Swedish cohort study of 6917 women aged between 50 and 59 even 192 
found a positive association between a high œstradiol level and UI (LE2) [27].  193 
 194 
3.5. Prevalence or incidence of UI depending on menopause hormonal treatment  195 
3.5.1. Data obtained from random studies of women treated for urinary symptoms 196 
A meta-analysis based on eleven randomised studies of the effects of œstrogen (versus 197 
placebo) on overactive bladder symptoms found a significant association between œstrogen 198 
treatments and an improvement in the urinary symptoms: less pollakiuria and nocturia, fewer 199 
episodes of UUI and urine leaks, improvement in the latence of the first urge to void and 200 
increase in bladder capacity (LE1) [28]. However the effects vary according to the mode of 201 
administration of the œstrogens. Local application (vaginal or intravesical) is associated in 202 
significant fashion with an improvement in all the urinary symptoms (pollakiuria, nocturia, 203 
UUI, bladder capacity). Systemic administration results in only partial improvement of these 204 
symptoms, and statistically is associated only with a drop in the number of episodes of 205 
incontinence and later perception of the first urge to void.  206 
A review of the literature covering several randomised trials (comparisons between different 207 
protocols for œstrogen treatment or versus placebo) confirms the advantage of vaginal 208 
treatments in case of post-menopausal lower urinary tract symptoms, especially in the 209 
presence of vaginal atrophy (LE2) [11]. The findings of recent studies of the effect of 210 
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œstrogens in association with anti-muscarini agents did not agree. A controlled study of 229 211 
femmes presenting an overactive detrusor did not show any benefit for topical vaginal 212 
œstrogen therapy associated with tolterodine versus tolterodine alone for overactive bladder 213 
symptoms (LE2) [29]. Another randomised controlled trial in 80 women with overactive 214 
bladder syndrome, also comparing the effect of topical vaginal œstrogen therapy associated 215 
with tolterodine with that of tolterodine alone, found a significant improvement of objective 216 
parameters and quality of life when œstrogens were associated with tolterodine (LE2) [30]. 217 
Finally, a recent randomised trial comparing the efficiency of topical vaginal œstrogen 218 
therapy with that of oxybutynin for the treatment of overactive bladder syndrome found that 219 
the two products were similar in terms of efficiency (LE2) [31]. 220 
A review of the literature covering eight controlled studies and 14 prospective non-controlled 221 
studies concluded that œstrogen treatment is not efficient for SUI (LE2) [32]. 222 
 223 
3.5.2. Data resulting from secondary analyses of randomised trials in the general 224 
population 225 
Among the post-menopausal women enrolled in the Womens’ Health Initiative study (WHI), 226 
HRT significantly increased the incident risk at one year of all types of UI (SUI, UUI, MUI) 227 
in women who were continent at the time they were included (LE2). This effect of HRT is 228 
particularly distinct for SUI and less so if at all for UUI [33]. In women taking oral œstrogens 229 
and progestin, the relative risk of de novo UI is 1.87 [1.61-2.18] for SUI, 1.15 [0.99-1.34] for 230 
UUI and 1.49 [1.10-2.01] for MUI. The results are similar for women taking œstrogen alone: 231 
2.15 [1.77-2.62], 1.32 [1.10-1.58], and 1.79 [1.26-2.53] respectively. In women who were 232 
incontinent when included, HRT slightly increased the quantity lost (1.20 [1.06-1.36] when 233 
treated using œstrogen and progestin and 1.59 [1.9-1.82] when treated with œstrogen alone), 234 
and the frequency of leaks (1.36 [1.28-1.49] and 1.47 [1.35-1.61] respectively) [33]. 235 
Steineauer et al. carried out a subsidiary analysis of the Heart Estrogen/Progestin 236 
Replacement Study (a double-blind randomised study assessing the effect of HRT for 237 
prevention of cardiovascular risks) concerning patients with no UI at inclusion [34]. A 238 
significant relationship between HRT and the onset of both UUI and SUI was found during 239 
the first four months of treatment. This detrimental effect of HRT persisted throughout the 4 240 
years of the study, with a cumulated additional risk of 12% and 16 % respectively for UUI 241 
and SUI compared with treatment by placebo (LE2).  242 
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The results of these studies were included and confirmed in the Cochrane Database [35] meta-243 
analysis which covered a total of 19 313 incontinent women among whom 9417 were treated 244 
by œstrogens, in 33 studies (16 of which addressed specifically SUI). There was no analysis 245 
by type of UI. A worsening of UI symptoms was found when HRT was taken systemically 246 
(RR= 1.32 [1.17-1.42]) (LE1). However, topical vaginal œstrogen therapy contributed 247 
towards remission of UI by improving both the episodes of urge urinary incontinence (0.74 248 
[0.64-086]) and pollakiuria (LE1).  249 
 250 
3.5.3. Data obtained from cohort studies 251 
The data of the Nurses’ Health Study addressing the impact of HRT on UI in a cohort of 252 
nurses aged between 30 and 55 at the time of inclusion were analysed by Grodstein et al. [36]. 253 
The occurrence of incident UI was associated in significant fashion with systemic hormone 254 
therapy whatever the type of HRT and mode of administration: oral œstrogen (RR= 1.54 255 
[1.44-1.65]), transdermal œstrogen (1.68 [1.41-2.00]), oral œstrogen and progestin (1.34 256 
[1.24-1.44]) and transdermal œstrogen and progestin therapies (1.46 [1.16-1.84]) (LE3). The 257 
overall risk of UI remained low however, with an annual incidence of 1.6%, and the effects of 258 
HRT disappeared when treatment ceased. 259 
A recent cohort study of post-menopausal women found an association between UI symptoms 260 
and duration of œstrogen treatment. Prolonged oral œstrogen therapy (5 years or more) is 261 
associated with a worsening of leakage symptoms (OR= 3.99 [1.21-13.1]) and also an 262 
increase in the frequency of handicapping UI (3.97 [1.02-15.4]) [37] (LE3). 263 
 264 
3.5.4. Data obtained from studies concerning intermediate markers 265 
Certain older studies report that the use of oral œstrogens appears to increase the urethral 266 
closing pressure and could thus improve SUI symptoms in 65 to 70% of women  [38] (LE5). 267 
Two randomised controlled trials concerning the oral route versus placebo to treat UI and 268 
including 83 and 67 post-menopausal women were unable to demonstrate any effect of 269 
œstrogens with respect to urodynamic parameters or urinary symptoms, whether in terms of 270 
objective measurements (pad-test, cystometrography, prolifometry) or in terms of subjective 271 
measurements (assessed by approved quality of life questionnaires) [39] (LE2). 272 
 273 
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3.5.5. Influence of hormonal treatment after surgery for SUI 274 
Certain studies looked at the impact of œstrogen therapy when surgery is used for SUI. A 275 
prospective randomised study comparing the effects of adjuvant topical vaginal œstradiol or 276 
not for six months immediately after surgical correction of SUI using a sub-urethral tape 277 
(TVT-O) in 183 post-menopausal patient, found that pollakiuria (2 vs. 11 %, p=0.02) and urge 278 
urinary incontinence (3 vs. 12 %, p= 0.01) alone were improved by hormone therapy (LE2) 279 
[40]. The objective parameters of the urodynamic tests remained unchanged in both groups 280 
(LE2). In a randomised controlled trial Zullo et al. found exactly the same results with urge 281 
urinary incontinence alone being improved by topical vaginal œstrogen therapy (LE2) [41]. 282 
No study of the long-term advantages of œstrogen after installation of a sub-urethral tape was 283 
found.  284 
 285 
4. Discussion 286 
The results of our review concerning the link between menopause and UI do not all agree, but 287 
this overview shows that the menopause has little if any impact on the risk of UI in general, 288 
when confounding factors such as age or changes in weight are taken into account. It appears 289 
that SUI decreases after the menopause while UUI or mixed UI increase at this time. Oral 290 
HRT has a rather detrimental effect on stress urinary incontinence, by doubling the risk of de 291 
novo SUI. Concerning UUI, HRT has less of an effect, which is variable according to the 292 
population in question and the type of treatment. Topical vaginal œstrogen therapy is the only 293 
treatment that seems to have a really beneficial effect on urge urinary incontinence or 294 
overactive bladder symptoms. 295 
Most of these results are drawn from longitudinal analyses of large cohorts enabling a 296 
distinction to be drawn between the effect of age and that of the menopause. Longitudinal 297 
studies are the only way to examine the timing, and consequently any cause and effect 298 
relationship between events. Cross-sectional studies cannot assess time-dependent variables 299 
such as age, weight and menopausal status. Nevertheless, the large cohort studies included in 300 
this review present several problems. For example, the definition of UI is not identical in all 301 
the studies because follow-up of the cohorts often started prior to the harmonisation of the 302 
terminologies proposed by ICS and IUGA. The frequency of UI as a "functional complaint" 303 
depends on the tools used. Moreover, few of the studies draw a distinction between the 304 
various types of UI (SUI, UUI, MUI), their frequency or their severity. Finally in this type of 305 
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cohort, the lack of any overall assessment of incontinence risk factors (because the studies 306 
were not designed initially to study this problem specifically) can result in confounding 307 
biases. 308 
Part of the results of this review is based on secondary analyses of randomised trials in which 309 
the main objective was not to study UI but instead the cardiovascular morbidity of HRT. So 310 
the level of evidence contributed by these secondary analyses is lower. 311 
Certain pathophysiological data would tend to indicate a worsening of UI due to lack of 312 
œstrogen. However, in contradiction with this postulate, the epidemiological data obtained 313 
with the cohorts shows that the menopause has little if any effect on urinary symptoms. The 314 
results of several large randomised trials in the general population reveal an aggravation of UI 315 
in case of systemic HRT. This detrimental effect of HRT needs to be seen in the light of what 316 
is observed during pregnancy, when an increase in the prevalence of UI is observed [42]. This 317 
greater prevalence of UI during pregnancy could be explained by the increase in œstrogen 318 
concentrations.  319 
Topical vaginal œstrogen therapy alone appears to have a beneficial effect on overactive 320 
bladder symptoms. This effect could be explained by the improvement in terms of vaginal 321 
dryness and a drop in recurrent urinary infections [8,11]. The learned societies do not 322 
recommend the use of œstrogens (whether or not associated with progesterone) for the 323 
treatment of UI. However, in case of overactive bladder symptoms in a post-menopausal 324 
woman, topical vaginal treatment may be proposed [43,44]. 325 
 326 
5. Conclusion 327 
Female urinary incontinence is a complex and dynamic phenomenon, related with age and a 328 
many other factors that can change with time. In order to gain greater insight, longitudinal 329 
studies are necessary, with several years or even decades of follow-up in order to clarify its 330 
evolution and risk factors.  331 
The onset and/or worsening of UI at the menopause that is expected on the basis of 332 
physiological observations is not confirmed by the results of most of the epidemiological 333 
studies that mostly cover a large number of women followed up over many years. Moreover, 334 
correction of the lack of œstrogen by HRT gives rise to paradoxical results that depend on the 335 
type of UI and mode of administration. Systemic œstrogen therapy results in an increase in UI 336 
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symptoms and SUI in particular. Topical vaginal administration appears to be the most 337 
beneficial by improving overactive bladder symptoms.  338 
 339 
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